UNICYCIVE THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $14.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $8.17M.
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$6.37M, a 116.25% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $39.23M, a 64.30% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $23.88M.
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $3.06M, a 81.41% decline from fiscal 2024.
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $16.44M, a 77.82% increase from fiscal 2023.
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $9.25M.
- UNICYCIVE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$16.12M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.99M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $8.17M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $3.06M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $16.55M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | -$3.81M 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | -$6.37M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $16.44M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $22.65M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $32.08M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $39.23M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $9.25M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $13.89M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $18.36M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | $23.88M 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | -$16.12M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | -$9.57M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |